checkAd

     405  0 Kommentare Medivation to Present at Leerink Partners 5th Annual Global Healthcare Conference

    SAN FRANCISCO, CA--(Marketwired - Jan 27, 2016) - Medivation, Inc. (NASDAQ: MDVN) today announced that David Hung, M.D., founder, president and chief executive officer and Rick Bierly, chief financial officer will participate in a fireside chat at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 8:50am ET at the Waldorf Astoria Hotel in New York, NY.

    Individuals may access the live audio webcast by visiting: http://investors.medivation.com/events.cfm. A replay of the webcast will be available on the Company's website for 30 days following the live event.

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Pfizer!
    Short
    30,22€
    Basispreis
    0,24
    Ask
    × 10,77
    Hebel
    Long
    25,24€
    Basispreis
    0,25
    Ask
    × 10,34
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    About Medivation
    Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at http://www.medivation.com.

    Contacts:
    Anne Bowdidge
    Sr. Director, Investor Relations
    (650) 218-6900





    Verfasst von Marketwired
    Medivation to Present at Leerink Partners 5th Annual Global Healthcare Conference SAN FRANCISCO, CA--(Marketwired - Jan 27, 2016) - Medivation, Inc. (NASDAQ: MDVN) today announced that David Hung, M.D., founder, president and chief executive officer and Rick Bierly, chief financial officer will participate in a fireside chat at …

    Schreibe Deinen Kommentar

    Disclaimer